Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure

Abstract

Background-Vessel dilator, a 37-amino acid peptide hormone synthesized in the heart, enhances urine flow 4-to 12-fold and sodium excretion 3-to 6-fold in healthy humans. The present investigation was designed to determine whether vessel dilator might have similar beneficial effects in persons with congestive heart failure (CHF). Methods and Results-Vessel dilator (100 ng/kg body weight per minute) given intravenously for 60 minutes to NYHA class III CHF subjects increased urine flow 2-to 13-fold, which was still increased (PϽ0.001) 3 hours after its infusion was stopped. Vessel dilator enhanced sodium excretion 3-to 4-fold in CHF subjects (PϽ0.01), which was still significantly (PϽ0.01) elevated 3 hours after infusion. Vessel dilator decreased systemic vascular resistance 24%, pulmonary vascular resistance 25%, pulmonary capillary wedge pressure 33%, and central venous pressure 27% while increasing cardiac output 34%, cardiac index 35%, and stroke volume index 24% without significantly affecting heart rate or pulmonary artery pressure in the CHF subjects. The control CHF patients did not have any changes in the above parameters. Conclusions-These results indicate that vessel dilator has significant beneficial diuretic, natriuretic, and hemodynamic properties in humans with congestive heart failure. (Circulation. 1998;98:323-329.)

Primary Malignant Tumors of the Heart: Four Cardiovascular Hormones Decrease the Number and DNA Synthesis of Human Angiosarcoma Cells

“…The cardiovascular hormones do not produce myelosuppression or cardiomyopathy [19,20,21]. These peptide hormones which normally circulate in the human body [26,27,28,29,30,31] have no cytoxic effects on normal cells [4] and only one known side effect [12,13,14,15,16,17,18,19,20,21,22,23,24]. This side effect, i.e.…”

“…hypotension, has only been observed with ANP and BNP and never with vessel dilator, LANP or kaliuretic peptide, i.e. the cardiovascular hormones with the best safety profile [12,13,14,15,16,17,18,19,20,21,22,23,24]. …”

“…Within the 126-aa ANP prohormone are four peptide hormones whose main known biologic properties are blood pressure regulation and maintenance of plasma volume in animals [12,13,14,15,16,17,18] and humans [19,20,21]. These peptide hormones are LANP, vessel dilator, kaliuretic peptide and ANP [11, 22].…”

Heart Peptide Hormones: Adjunct and Primary Treatments of Cancer

“…On the other hand, the treatment of congestive heart failure with vessel dilator in humans was via intravenous infusion (105). To determine which of these methods might be best for treating humans with cancer, pharmacokinetics were compared between intravenous bolus (IvB), subcutaneous bolus (ScB) and subcutaneous infusion for 3 hours in male Fischer 344 rats (106).…”

Urodilatin: A better natriuretic peptide?

“…1). Within the 126 a.a. prohormone in the heart are four peptide hormones whose main biologic properties are blood pressure regulation and maintenance of plasma volume in animals [5][6][7][8][9][10][11] and humans [12][13][14][15][16]. These peptide hormones, numbered by their a.a. sequences beginning at the N-terminal end of the ANP prohormone, consist of the first 30 a.a. of the prohormone-that is, long acting natriuretic peptide (LANP), vessel dilator (a.a. 31-67), kaliuretic peptide (a.a. 79-98), and ANP (a.a. 99-126) [2,3].…”